US 10,117,889 B2Granted

Antibodies specific for LOX1 and use in treatment of cardiovascular disorders

AssigneeMedImmune, LLC

InventorsAndrew Buchanan, Matthieu Chodorge, Peter Cariuk, Johanna Husmark, Clare Balendran, Deepesh Pandey, Fumin Chang, Daniel E. Berkowitz, Lewis H. Romer

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

Claims20

Dependent claims

An isolated Lectin-like oxidized low density lipoprotein receptor-1 (LOX1) antibody comprising a set of complementary determining regions (CDRs):

heavy chain variable region (VH)-CDR1, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDR1, VL-CDR2 and VL-CDR3, wherein:
(a) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:2;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:3;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:30;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:31;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:32;
(b) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:5;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:14;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:30;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:31;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:32;
(c) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:38;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:39;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:44;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:60;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:61;
or
(d) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:38;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:39;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:40;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:56;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:57.

27 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/516,115Filed 30 Sep 2015 · us provisional application
Priority: 1 Oct 2014
Published: US 2017/0304343 A126 Oct 2017
Granted: 6 Nov 2018
Term ends: Not estimatedThe source records don’t support an estimate.

Classification36 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 9/04
Drugs for disorders of the cardiovascular system: inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Family

Application62/058,254Us provisional application · filed 1 Oct 2014
US 2017/0304343 A1Pre-grant publication · published 26 Oct 2017
US 10,117,889 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key